Cost‐effectiveness analysis of therapeutic strategies for patients with chronic hepatitis C previously not responding to interferon
Authors:
- R. San MiguelRMR. San Miguel
- J. MarJMJ. Mar
- J M CabasésJCJ M Cabasés
- J. M.JMJ. M.
- F. Guillén‐GrimaF. Guillén‐Grima
- M. ButiMBM. Buti
- 17 March 2003
- journal article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 17 (6) , 765-773
Abstract
Summary: Background: The efficacy of combination therapy in patients with chronic hepatitis C previously not responding to interferon monotherapy is lower than that in naive patients, and there has been no economic evaluation in this population.Aim: To develop a cost‐effectiveness analysis of therapeutic regimens with interferon‐alpha and ribavirin in previous interferon non‐responders.Methods: A Markov simulation model was used to project the clinical and economic outcomes of five different therapeutic strategies, including a ‘no treatment’ alternative, using the health care system perspective. The efficacy data for the different doses and durations were obtained from a previously performed meta‐analysis. A sensitivity analysis was performed to test the robustness of the model, analysing changes in different variables.Results: Applying a 3% discount rate, the standard patient on combination therapy for 12 months showed increases of 0.80 years and 1.55 quality‐adjusted life years, when compared with the ‘no treatment’ strategy. This option led to an incremental cost‐effectiveness ratio of 11 767 euros per year of life gained and 6073 euros per quality‐adjusted life year.Conclusions: Combination therapy with interferon plus ribavirin is cost‐effective in previous interferon non‐responders and is within the range of some well‐accepted medical interventions in our health care system.Keywords
This publication has 25 references indexed in Scilit:
- Management Strategies for Ribavirin-Induced Hemolytic Anemia in the Treatment of Hepatitis C: Clinical and Economic ImplicationsValue in Health, 2001
- A Randomized 4–Arm Multicenter Study of Interferon Alfa-2B Plus Ribavirin in the Treatment of Patients With Chronic Hepatitis C Not Responding to Interferon AloneHepatology, 2001
- Pilot dose-finding trial on interferon alpha in combination with ribavirin for the treatment of chronic hepatitis C in patients not responding to interferon aloneDigestive and Liver Disease, 2001
- Cost-effectiveness of combination therapy for naive patients with chronic hepatitis CNoteJournal of Hepatology, 2000
- A Comprehensive League Table of Cost-Utility Ratios and a Sub-table of "Panel-worthy" StudiesMedical Decision Making, 2000
- Cost effectiveness of interferon α2b combined with ribavirin for the treatment of chronic hepatitis CHepatology, 1999
- The Prevalence of Hepatitis C Virus Infection in the United States, 1988 through 1994New England Journal of Medicine, 1999
- EASL International Consensus Conference on Hepatitis C Paris, 26–28 February 1999Journal of Hepatology, 1999
- Interferon in WonderlandGastroenterology, 1998
- Therapy of hepatitis C: Meta-analysis of interferon alfa-2b trialsHepatology, 1997